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Duchenne (DMD) and golden retriever (GRMD) 
 muscular dystrophy are caused by genetic mutations 
in the dystrophin gene and afflict striated muscles. We 
investigated systemic gene delivery in 4-day-old GRMD 
dogs given a single intravenous injection of an AAV9 
vector (1.5 × 1014 vector genomes/kg) carrying a human 
codon-optimized human mini-dystrophin gene under 
control of the cytomegalovirus (CMV) promoter. One of 
the three treated dogs was euthanized 9 days later due 
to pre-existing conditions. Scattered mini-dystrophin-
positive myofibers were seen by immunofluorescent (IF) 
staining in numerous muscles. At the end of the 16-week 
study, the other two dogs showed generalized muscle 
expression of mini-dystrophin in ~15% to nearly 100% 
of myofibers. Western blot and vector DNA quantitative 
PCR results agreed with the IF data. Delayed growth 
and pelvic limb muscle atrophy and contractures were 
seen several weeks after vector delivery. T-2 weighted 
magnetic resonance imaging (MRI) at 8 weeks showed 
increased signal intensity compatible with inflammation 
in several pelvic limb muscles. This marked early inflam-
matory response raised concerns regarding methodo-
logy. Use of the ubiquitous CMV promoter, extra-high 
vector dose, and marked expression of a human protein 
in canine muscles may have contributed to the patho-
logic changes seen in the pelvic limbs.
Received 26 January 2010; accepted 20 April 2010; published online  
1 June 2010. doi:10.1038/mt.2010.94
IntroductIon
Duchenne muscular dystrophy (DMD) is an X-linked recessive 
disorder affecting ~1 of 3,500 newborn human males in whom 
absence of the protein dystrophin causes progressive degeneration 
of skeletal and cardiac muscles.1 No treatment halts or reverses 
progression of DMD. Although cellular and gene therapies are 
promising, key questions must first be addressed in relevant  animal 
models. Spontaneous forms of X-linked muscular dystrophy due 
to dystrophin deficiency have been identified in mice,2,3 multiple 
dog breeds,4–7 and cats.8,9 Unlike the dystrophin-deficient mdx 
mouse, which shows relatively mild clinical signs, affected dogs 
develop progressive, fatal disease strikingly similar to the human 
condition. Accordingly, studies in the canine dystrophin-deficient 
models, such as golden retriever muscular dystrophy (GRMD), 
may be more likely than those in mdx mice to predict pathogen-
esis and treatment outcome in DMD.
Adeno-associated virus (AAV)–mediated mini- and micro-
dystrophin gene therapy has shown promise in mdx mice, with 
widespread expression demonstrated after systemic delivery in 
neonatal10 and older mice with chronic disease.11 However, use of 
AAV-mediated gene therapy in murine models of other diseases 
such as hemophilia has not consistently predicted the degree of 
immunologic response.12 In keeping with this species dichotomy 
and in contrast to findings in mdx mice, studies of localized (intra-
muscular) AAV-mediated dystrophin mini (or micro) gene therapy 
in GRMD dogs have documented a marked immune response to 
either components of the transgene (to include dystrophin)13 and/
or viral capsid proteins.14,15 Because of the relative immaturity of 
the neonatal immune system, animals treated soon after birth may 
mount a less robust response. Indeed, long-term, widespread mus-
cular transduction with a human placental alkaline phosphatase 
reporter gene has been reported after systemic intravenous  delivery 
of an AAV9 construct in normal, neonatal dogs.16
Here, we report findings from three GRMD dogs that were 
administered an AAV9-CMV-human mini-dystrophin construct 
intravenously at 4 days of age. Although widespread muscle 
expression of mini-dystrophin was seen 16 weeks after treat-
ment, the affected dogs also had pelvic limb muscle atrophy and 
contractures, apparently associated with an early innate immune 
response.
results
clinical and pathologic findings in individual dogs
All three GRMD dogs were homozygous females. Each 
had elevation of serum creatine kinase on the day of birth: 
RaF7 (>300,000 U/l), Emerald (241,200 U/l), and Amethyst 
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(294,000 U/l). One of the dogs (RaF7) was lethargic and stunted 
(birth mass of 194 g compared to 275–290 g for its four GRMD lit-
termates) prior to vector injection and was euthanized 9 days later 
due to persisting lethargy and anorexia. On histologic evaluation 
of the liver, there was marked steatosis confined to the left medial 
lobe, most likely due to a congenital condition unrelated to vector 
delivery. The rest of the liver was grossly and histologically normal 
(Supplementary Figure S1).
The other two treated homozygous female GRMD dogs 
(Emerald and Amethyst) had delayed growth compared to two 
untreated GRMD male littermates (Jasper and Peridot) and two 
untreated homozygous affected females born in a  different  litter 
3 days later (Hope and Vasalia) (Supplementary Figure S2). 
Although all six dogs were of near equal size at birth, by 16 weeks, 
the two treated females weighed considerably less than the 
untreated dogs [note that GRMD males typically weigh ~15% more 
than homozygous GRMD females at 6 months (J.N. Kornegay 
and D.J. Bogan, unpublished results)]. Emerald and Amethyst 
developed pelvic limb muscle atrophy and contractures that were 
most pronounced in the right pelvic limb of Emerald. The stifle 
(knee) joint was locked in extension, consistent with quadriceps 
contracture seen in dogs with inflammatory neuromyopathies.17 
Figure 1 Histopathological changes in muscles 16 weeks after AAV9-cMV-mini-dystrophin vector intravenous injection of golden retriever 
muscular dystrophy (GrMd) dogs emerald (e) and Amethyst (A) at 4 days of age. (a) Semitendinosus (E), (b) psoas major (E), (c) peroneus lon-
gus (A), (d) diaphragm (E), (e) cranial tibial (A), and (f) vastus medialis (E). All muscles have changes typical of GRMD, including small group myofiber 
necrosis (arrows in b, d, and e) and regeneration (arrows in c). Muscle is otherwise relatively normal histologically in all but the vastus medialis (f) in 
which marked deposition of fat is evident. Hematoxylin and eosin; bar = 300 µm.
table 1 serum chemistry values
test/
week
emerald Amethyst Visalia Hope Bryce
d0 4 8 12 0 4 10 12 0 4 8 12 0 4 8 12 0 4 8 12
CK (U/l) 241,200 4,500 12,450 8,480 294,000 313 5,680 23,120 90,400 14,080 11,100 11,600 137,000 689 42,900 2,630 3,000 316 313 453
BUN  
(mg/dl)
18 8 12 11 23 6 13 16 23 8 3 7 20 9 6 7 23 7 7 9
GGT (U/l) 7 16 16 16 NA 9 6 16 42 16 16 9 NA 9 8 8 68 20 7 9
ALT (U/l) 112 177 242 364 225 106 298 415 227 171 310 311 193 151 313 278 29 8 54 38
AST (U/l) 890 79 142 299 2,548 78 351 441 1,100 323 408 355 650 151 402 633 142 11 26 19
Alk phos 
(U/l)
532 122 58 62 624 129 97 91 656 96 73 48 871 144 89 64 703 148 141 162
Total Bili 
(mg/dl)




3.8 4.0 5.4 5.5 4.2 4.1 5.6 5.9 4.5 4.1 6.6 4.8 4.4 3.8 6.1 NA 3.7 4.1 4.7 6.0
Emerald, Amethyst, Visalia, and Hope are all homozygous female GRMD dogs; Bryce is a normal male dog. An 8-week sample was not available for Amethyst. 
Alk phos, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Bili, bilirubin; BUN, blood urea nitrogen; CK, creatine kinase; 
GGT, gamma-glutamyl transferase; NA, not applicable.
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Both dogs were active and alert despite their impaired pelvic 
limb function. Serum chemistries of all four dogs at 1, 2, 4, 6, 8, 
and 12 weeks were largely unremarkable, except for elevation of 
creatine kinase, alanine aminotransferase, and aspartate amino-
transferase (Table 1), which are associated with muscle necrosis 
in GRMD.18 On electromyography at 16 weeks, there were pro-
nounced complex repetitive discharges in pelvic limb muscles, 
consistent with prior reports,4,19 but no evidence of denervation 
in the pelvic limb muscles. Nerve conduction velocity was normal 
(data not shown).
Emerald and Amethyst were euthanized at 16 weeks. At 
necropsy, the quadriceps femoris muscle of Emerald was atro-
phied and the stifle (knee) could not be flexed. Characteristic 
small group myofiber necrosis and regeneration was present in all 
muscles. However, histopathological changes were relatively mild 
in all but the quadriceps muscle in which there was marked fatty 
deposition, especially in the vastus medialis head (Figure 1).
MrI
T2-weighted magnetic resonance imaging (MRI) 8 weeks after 
perfusion showed increased signal intensity in several proxi-
mal pelvic limb muscles of Emerald and Amethyst (Figure 2). 
The quadriceps femoris and adductor muscles were particularly 
involved in both dogs. Individual heads of the quadriceps were 
poorly defined, but signal intensity was most pronounced in the 
vastus intermedius and medialis. These increases in signal inten-
sity persisted with fat saturation in keeping with a fluid signal most 
likely associated with edema due to inflammation. MRI findings 
were largely consistent with histopathological changes.
Analyses of mini-dystrophin gene expression  
in various muscle groups
Immunofluorescent staining for mini-dystrophin was done in 
the muscles of all three treated dogs. In RaF7, who was eutha-
nized 9 days after vector delivery, scattered mini-dystrophin 
transgene-positive myofibers were observed in numerous muscle 
groups (Supplementary Figure S3), indicating that widespread 
mini-dystrophin gene expression occurred as early as 9 days after 
intravenous AAV9 injection. In Emerald and Amethyst, who 
were euthanized 16 weeks after vector delivery, widespread and 
high-level expression of mini-dystrophin was observed in mul-
tiple muscles, ranging from ~15 to nearly 100% of the myofibers 
being positive for mini-dystrophin staining (Figure 3a,b). Areas 
in which there was near uniform mini-dystrophin expression 
did not have dystrophic lesions and no inflammatory cell infil-
trate (Figure 4). Western blot analysis (Figure 5) and quantitative 
PCR on vector DNA (Figure 6) were generally consistent with the 
immunofluorescent (IF) results. Interestingly, pelvic limb muscles 
with a lower percentage of mini-dystrophin-positive myofibers by 
IF staining (e.g., rectus femoris) had an even higher quantity of 
the protein on western blot than the thoracic limb muscles (e.g., 
long head triceps), which had nearly 100% positive myofibers 
(comparing Figures 5 and 6), suggesting that individual mini-
dystrophin-positive myofibers in the pelvic limb muscles had 
higher transgene expression.
dIscussIon
These results support the feasibility of systemic intravenous 
delivery of truncated forms of dystrophin to skeletal muscles of 
neonatal GRMD dogs by AAV vectors. There was widespread 
transduction of skeletal muscles in the two dogs, Emerald and 
Amethyst, with nearly 100% of myofibers of some muscles being 
positive for mini-dystrophin gene expression 16 weeks after per-
fusion (duration of study). Although the long-term expression 
of mini-dystrophin is encouraging, the apparent myositis with 
contractures in these two dogs raises questions about the relative 
roles that AAV capsid antigens or the transgene itself may have 
played to induce an immune response. Others have documented 
a marked inflammatory response to either the transgene13 and/or 
viral capsid proteins14,15 in GRMD dogs injected intramuscularly 
with AAV-micro-dystrophin constructs. The immune responses 
were T-cell mediated and eventually eliminated micro-dystrophin 
expression in the vector-injected muscles. An analogous humoral 
immune response to the transgene has been seen in hemophiliac 
dogs following intramuscular injection of AAV2-Factor IX con-
structs.20 With both the hemophiliac and GRMD dogs, the immune 
response was blunted with transient immunosuppression.20,21
Immune function has traditionally been divided between 
innate and adaptive components. The innate immune system is 
generally thought to provide an immediate, nonspecific response 
to foreign antigens that confers no lasting immunity. In contrast, 
adaptive immunity is delayed, requires activation of specific clones 
of  lymphocytes, and leads to persisting immunity.22–24 The lack 
of a sustained immune reaction to the AAV9-mini-dystrophin 
Cranial sartorius Caudal sartorius Rectus femoris Gracilis
Quadriceps vastus heads Biceps femoris Semimembranosus
Adductor Semitendinosus
Figure 2 t2-weighted magnetic resonance images of pelvic limb 
muscles 8 weeks after AAV9-cMV-mini-dystrophin vector intrave-
nous injection of golden retriever muscular dystrophy dogs emerald 
and Amethyst at 4 days of age. Transverse (left) and sagittal (right) 
images of (a–d) Amethyst and (e–h) Emerald are seen. The images in 
c,d,g, and h have been segmented and color coded to outline individual 
muscles. Signal intense lesions are particularly pronounced in the vastus 
heads of the quadriceps and adductor muscles. These changes persisted 
with fat saturation suggesting that they most likely represent fluid due 
to inflammation or edema.
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construct in these dogs argues against a specific adaptive immune 
reaction. Factors contributing to long-term mini-dystrophin 
expression in these dogs could include the relative immaturity 
of the neonatal immune system, lower antigen loads in muscle 
with systemic versus localized vector administration, and the 
potential for a lower immune profile with AAV9. Unlike rodents, 
the immune system of humans and dogs is essentially mature at 
birth.25 However, neonatal dogs have lower immunoglobulin lev-
els and fewer T versus B lymphocytes. Moreover, their peripheral 
blood lymphocytes respond less vigorously to antigens in vitro. 
Cranial tibial Vastus intermedius
Vastus lateralis
Vastus medialis
Peroneus longus Longissimus Diaphragm
Cranial tibial Vastus intermedius Peroneus longus Longissimus Diaphragm
Cranial sartorius Intercostal Psoas Heart
Long digital extensor Biceps femoris Rectus femoris
Lateral head, gastrocnemius Semitendinosus Long head triceps Temporalis
Vastus lateralis
Vastus medialis
Cranial sartorius Intercostal Psoas Heart
Long digital extensor Biceps femoris Rectus femoris
Lateral head, gastrocnemius Semitendinosus Long head triceps Temporalis
a
b
Figure 3 Body-wide extensive human mini-dystrophin expression 16 weeks after intravenous injection of AAV9-cMV-mini-dystrophin vector 
in golden retriever muscular dystrophy dogs (a) emerald and (b) Amethyst at 4 days of age. Cryo-thin sections of the muscle and heart were 
stained by immunofluorescence with antibody against human mini-dystrophin (red color) and counterstained with DAPI to show cell nuclei (blue 
color). Variable and extensive gene expression in multiple skeletal muscles is readily visible. Photomicrographs were taken from the areas of best mini-
dystrophin expression in each muscle. a,b, Bar = 250 µm.
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Taken together, these differences could dampen the immune 
response of neonatal dogs to antigens such as AAV or mini-
dystrophin. Prior studies of the immunogenicity of AAV-mini-
dystrophin constructs in dogs have focused on intramuscular 
delivery.13–15,21 Studies have also demonstrated long-term expres-
sion of Factor IX in dogs following intramuscular injection of AAV 
constructs.20,26 Although such localized approaches reduce the risk 
of systemic side effects, an immune response may be more likely 
in muscle, simply because of the concentrated antigen load. Other 
studies of AAV in GRMD and hemophiliac dogs have mostly used 
either AAV2 or 6, although AAV9 was employed in dogs of this 
report and an earlier study in which the human alkaline phos-
phatase gene was expressed in neonatal dogs.16 In general, AAV 
capsid antigens are remarkably conserved across serotypes,27 with 
the AAV8 capsid amino-acid sequence being 83% conserved com-
pared to AAV2. Other distinguishing features such as the kinetics 
of vector uncoating also influence the immune response. AAV2 
slowly uncoats, thus potentially allowing more time for capsid 
peptides to be presented to immune cells.28 On the other hand, 
based on results from hemophiliac dogs, the fact that AAV2 trans-
duces muscle less efficiently than certain AAV serotypes reduces 
expression of Factor IX and the associated immune response.12 
Although studies in mice and nonhuman primates have suggested 
that AAV serotypes that do not bind heparan sulfate proteogly-
cans are less able to activate T cells after intramuscular injection,29 
use of the nonheparin-binding AAV1 serotype did not eliminate 
immunogenicity in GRMD dogs.15
Just as multiple factors may have allowed long-term expression 
of the transgene in these dogs, several elements potentially con-
tributed to the inflammatory reaction. Both the AAV9 vector and 
the transgene should be considered. It is unlikely that the immune 
response was triggered by protein impurities in the AAV9 vector 
preparations. Protein gel examination showed that the final vector 
preps used in the in vivo study were >95% pure (Supplementary 
Figure S4). Nonetheless, we cannot completely rule out the possi-
bility that vector impurities contributed to the response. While pre-
 existing immunity to AAV antigenic epitopes could have led to the 
immune response, our prior studies have found no such antibodies 
in naive dogs of various ages in the colony (data not shown). The 
10–60% homo logy between the canine parvovirus capsid protein 
and that of AAV6 could predispose dogs to an immune reaction. 
But,  others have shown that vaccination with canine parvovirus 
does not induce a humoral immune response to AAV.15 In their 
hands, there was  limited or no homology between canine parvo-
virus and the epitopes of AAV6 that were identified to be immu-
nogenic. Another study used AAV9 vector to express the human 
placental alkaline phosphatase reporter gene under transcriptional 
control of the ubiquitous Rous sarcoma virus promoter in normal 
neonatal dogs without side effects.16 Separately, we have also used an 
AAV9 vector to express either canine mini-dystrophin (two dogs; 
4 months old) or codon-optimized human mini-dystrophin (one 
dog; 2 months old), both under control of the human cytomega-
lovirus (CMV) promoter.30 Each construct was injected intrave-
nously into a  pelvic limb isolated from the general circulation using 
a tourniquet in the inguinal area (hydrodynamic limb perfusion). 
Widespread mini-dystrophin expression was observed in all three 
dogs at the time of the last biopsy at 1 year, 1.5 years, and 2 years 
after perfusion (J. Li, J.R. Bogan, D.J. Bogan, J.N. Kornegay, and X. 
Xiao, unpublished results), again arguing against cellular immune 
responses toward the vector-transduced myofibers. However, tran-
sient inflammation was observed in the limb that was perfused 
with the human codon-optimized human mini- dystrophin, sug-
gesting this as the source of the immune reaction. We had previ-
ously largely shifted to canine mini- dystrophin but chose to use the 
human version in these dogs for the sake of the codon optimiza-
tion, which generated approximately tenfold higher gene expres-
sion than the nonoptimized one when examined in mdx mice. 
Besides the potential antigenicity of the human mini-dystrophin, 
the remarkably high vector dose (1.5 × 1014 viral genomes/kg) and 
greatly enhanced expression due to codon optimi zation may have 
led to extremely high-level expression in some muscles such as the 
quadriceps and also in nonmuscle  tissues, thus triggering an innate 
immune response. Use of the same vector and dose caused similar 
side effects in neonatal dystrophin–utrophin double knockout mice 
with an immature immune system. A tenfold lower dose rendered 
profound therapeutic benefits in these mice without apparent side 
effects (P. Hu, B. Wang, J. Li, and X. Xiao, unpublished results). 
Although an adaptive cellular immune response could not be ruled 
DYS DYS + CD4 
SG-γ DYS + CD8 
DYS + SG-γ H&E 
Figure 4 lack of immune infiltration and dystrophic lesions in 
muscles with uniform human mini-dystrophin expression 16 weeks 
after intravenous injection of AAV9-cMV-mini-dystrophin vector 
in golden retriever muscular dystrophy dog emerald at 4 days of 
age. The long head of the triceps muscle of Emerald was cryo-thin-
sectioned. Consecutive sections were subjected to H&E and fluorescent 
staining with antibodies against mini-dystrophin (DYS, green color), 
sarcoglycan-γ (SG-γ, red color), CD4 (red color), and CD8 (red color) 
T cells. Note the lack of T-cell infiltration and dystrophic lesions in the 
muscle. Bar = 150 µm. H&E, hematoxylin and eosin.
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out in the GRMD dogs reported here, the long-term body-wide 
human mini-dystrophin expression and lack of T-cell infiltration 
are more consistent with innate immunity. The precise underlining 
mechanisms remain elusive and require further study.
The clinical syndrome of contractures and associated MRI find-
ings in these dogs warrants special comment. Inflammatory muscle 
disease characteristically causes signal intense lesions on T2-weighted 
MR images.31,32 These changes do not suppress with fat saturation and 
are thought to reflect a fluid signal subsequent to edema. Somewhat 
analogous but less severe lesions occur in GRMD muscle indepen-
dent of treatment, presumably because of inflammation and edema 
associated with muscle necrosis,33 and have also been reported in 
GRMD dogs treated with AAV vectors.15 The preferential involve-
ment of the vastus heads of the quadriceps femoris and adductor 
muscles is in keeping with selective involvement of certain muscles 
in inflammatory myopathies in both humans and dogs. In particular, 
the vastus heads of the quadriceps are dramatically affected despite 
sparing of the  rectus femoris in humans with sporadic inclusion 
body myositis.34 Similarly, some dogs with Neospora caninum infec-
tion develop hyperextension of the stifle (knee) (genu recurvatum) 
secondary to quadriceps myositis and contractures akin to those 
seen in Emerald,17 suggesting that those muscles are more sensitive 
to inflammation. Reasons for this predominant involvement of par-
ticular muscles have not been defined in either disease.
Studies of gene therapy for DMD have been facilitated by the 
availability of both small (mdx) and large (GRMD) animal  models. 
Results from mdx mice have largely supported application to 
human patients, although those from GRMD have identified risks 
of immune rejection. Our findings support the potential use of 
systemic gene therapy in DMD but also point to potential risks. 
























































































































































































































Figure 5 Analyses of mini-dystrophin expression by western blot in muscle and heart samples at necropsy 16 weeks after intravenous 
 injection of AAV9-cMV-mini-dystrophin vector in golden retriever muscular dystrophy dogs emerald and Amethyst at 4 days of age. Human 
mini-dystrophin and low levels of endogenous revertant dystrophin are seen in nearly all skeletal muscles. Low levels of human mini-dystrophin are 




























































































Figure 6 Analysis of AAV vector dnA by quantitative Pcr in muscle 
and heart samples at necropsy 16 weeks after intravenous injection 
of AAV9-cMV-mini-dystrophin vector in golden retriever muscular 
dystrophy dogs emerald and Amethyst at 4 days of age. Numbers are 
shown on a per nucleus (diploid genome) basis. The data were obtained 
by dividing total vector copy numbers by 2 × the total copy numbers of 
an endogenous single-copy gene glucagon in the PCR reactions of each 
muscle sample.
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constructs have generally induced a more pronounced immune 
response in dogs.12 With this said, canine hemophilia studies did 
not predict a T cell–mediated response to AAV capsid antigens 
that destroyed transduced hepatocytes in a human trial.35 Further 
experiments in the GRMD model are needed to define the nature 
of the immune response to AAV-mini-dystrophin constructs.
MAterIAls And MetHods
Animals. This study involved three homozygous female GRMD dogs 
produced in a colony at the University of North Carolina at Chapel Hill 
(UNC-CH). Dogs were used and cared for according to principles out-
lined in the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. The phenotype was initially determined based on the 
elevation of serum creatine kinase and confirmed by PCR.
At 4 days of age, the three dogs weighed from 243 to 450 g. Butterfly 
catheters were placed in the jugular veins. Codon-optimized, AAV9-
CMV-human mini-dystrophin construct (1.5 × 1014 vg/kg) was suspended 
in 15 ml/kg of saline (total volume of 3.65–6.75 ml) and administered at a 
rate of ~1 ml/minute. The dogs were observed and weighed daily for the 
first 6 weeks and weekly thereafter.
Mini-dystrophin gene in AAV9 vectors. The human mini-dystrophin gene 
(DysΔ3990), as reported previously,36 was modified by human codon usage 
optimization and fully synthesized (GeneArt, Toronto, Ontario, Canada). 
The optimized mini-dystrophin, named opti-DysΔ3978, encodes the same 
protein as its precursor but with optimized DNA sequences for better RNA 
processing and protein translation. The opti-DysΔ3978 mini-dystrophin 
gene was subcloned into an AAV expression vector cassette under tran-
scriptional control of a CMV promoter for strong expression.36 The opti-
DysΔ3978 mini-dystrophin gene expression vector was then packaged into 
AAV9 capsids37 and purified by double CsCl density ultracentrifugation 
using previously published adenovirus-free, triple plasmid transfection 
protocols.38 The vector titers were determined by DNA dot blot at ~1 × 
1013 viral genome particles per ml in 1× phosphate-buffered saline solution 
plus 3% sorbitol.
IF staining and western blot. IF staining of mini-dystrophin in the cardiac 
and skeletal muscles of the GRMD dogs after AAV9 vector gene transfer 
was performed similarly using a protocol described previously.36 Briefly, 
the snap-frozen tissues were cryo-thin-sectioned at 8 µm thickness and 
blocked with 5% horse serum in phosphate-buffered saline without prior 
fixation. Polyclonal primary antibodies were used for immunostaining of 
dystrophin (anti-Rod1 and Rod2 regions of human dystrophin 1:500). 
Monoclonal primary antibodies were used for the immunostaining of 
γ-sarcoglycans at 1:100 dilution (NCL-g-SARC; Novocastra, Burlingame, 
CA). IF staining of canine CD4+ and CD8+ T cells was performed by 
monoclonal antibodies, rat anti-canine CD4 and CD8 IgGs at 1:100 dilu-
tion (Serotec, Oxford, UK). Two different fluorophore-labeled second-
ary antibodies were used in this study: red fluorescence (Cy3-conjugated 
AffiniPure goat anti-rabbit IgG, and Cy3-conjugated goat anti-mouse 
IgG and goat anti-rat IgG; Jackson ImmunoResearch, West Grove, PA) 
and green fluorescence (Alexa Fluor 488 chicken anti-rabbit IgG or goat 
anti-mouse IgG; Molecular Probes, Eugene, OR). All were diluted with 5% 
horse serum in 1× phosphate- buffered saline at 1:500 of ratio for use.
Western analysis for mini-dystrophin expression in dog muscle. Western 
analysis was carried out according to previously published methods.39,40 
Briefly, 20 cryosections of each muscle sample were lysed in 200 µl of 
protein lysis buffer with proteinase inhibitor cocktail (Sigma-Aldrich, 
St Louis, MO). After brief sonication and vortexing, the lysate was spun at 
12,000 rpm in 4 °C for 10 minutes and supernatant collected. The protein 
concentration was determined by the Bradford method (Bio-Rad protein 
assay; Bio-Rad Laboratories, Hercules, CA). A total of 20 µg protein per 
sample was boiled with sample loading buffer. The samples were sepa-
rated by 5% SDS-PAGE and electrotransferred to PVDF membranes. After 
blocking in 10% nonfat dry milk in TBS buffer (50 mmol/l Tris-Cl, pH 7.5, 
200 mmol/l NaCl) for 1 hour, the membranes were incubated with primary 
antibodies in TBS containing 0.5% Tween-20 (TTBS) at room tempera-
ture for 1 hour. A  rabbit polyclonal antibody recognizing human dystro-
phin rod 22 and rod 23 regions was used in this experiment with a 1:5,000 
dilution. Following primary antibody incubation and multiple rinses, the 
membranes were incubated with the secondary antibody, a goat anti-rab-
bit conjugated with horseradish peroxidase (Sigma-Aldrich) with 1:5,000 
dilution in 2% dry milk and TBS buffer. After 1-hour antibody incubation 
and three washes with TTBS buffer and once with TBS, the full-length dys-
trophin from normal dog muscle and AAV vector-derived human mini-
dystrophin protein bands were visualized with chemiluminescence reagent 
(DuPont NEN, Boston, MA) by exposure to X-ray film.
MRI. At 8 weeks after perfusion, dogs were premedicated with acepromaz-
ine maleate (0.2 mg/kg), butorphanol (0.4 mg/kg), and atropine sulfate 
(0.04 mg/kg), masked, and then intubated and maintained with isoflurane. 
Anesthetized dogs were positioned in ventral recumbency (prone  position) 
in a Siemens 3T Allegra Head-Only MRI scanner (Siemens, Erlangen, 
Germany) and Siemens standard CP Head Coil (Siemens). The pelvic 
limbs were extended caudally and positioned in the head coil centered at 
midfemur. An initial FISP pulse sequence was performed to localize the 
sagittal and transverse planes. Transverse images were then collected using 
a 3D TSE VFL sequence (TR 3,000 ms, TE 409 ms, FOV 230 × 210 mm). 
A total of 160 slices (0.9 mm; voxel size 0.9 mm3 for Emerald and 0.7 mm3 
for Amethyst) were collected extending from the hip to stifle joints. Images 
were collected with and without fat saturation. The scan time for each run 
was 11:38. The 3DT2 and 3DT2FS transverse images were reconstructed 
in the transverse orientation using the standard Siemens 3D MPR applica-
tion. Raw and reconstructed 3DT2 and 3DT2FS images were transferred to 
the image PACS system for download and image analysis.
suPPleMentArY MAterIAl
Figure S1. Photomicrographs from (a) grossly normal and (b) 
pale lobes of the liver of GRMD RaF7 9 days after AAV9-CMV-mini-
dystrophin vector intravenous injection at 4 days of age.
Figure S2. Body mass (g; vertical axis) versus age (weeks; horizontal 
axis) at 2-week intervals from birth to 16 weeks of two GRMD dogs 
(Emerald and Amethyst) after intravenous injection of AAV9-CMV-mini-
dystrophin vector at 4 days of age and two untreated male  littermate 
GRMD dogs (Peridot and Jasper) and two untreated homozygous 
GRMD females (Hope and Vasalia) born 3 days later.
Figure S3. Human mini-dystrophin expression in multiple muscles 9 
days after AAV9-CMV-mini-dystrophin vector intravenous injection of 
GRMD dog RaF7 at 4 days of age.
Figure S4. AAV9 viral vector purity examined by polyacrylamide gel 
electrophoresis (PAGE) and Coomassie blue staining.
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